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BACKGROUND AND PURPOSE
Augmented Na+/Ca2+ exchanger (NCX) activity may play a crucial role in cardiac arrhythmogenesis; however, data regarding
the anti-arrhythmic efficacy of NCX inhibition are debatable. Feasible explanations could be the unsatisfactory selectivity of
NCX inhibitors and/or the dependence of the experimental model on the degree of Ca2+i overload. Hence, we used NCX
inhibitors SEA0400 and the more selective ORM10103 to evaluate the efficacy of NCX inhibition against arrhythmogenic Ca2+i
rise in conditions when [Ca2+]i was augmented via activation of the late sodium current (INaL) or inhibition of the Na+/K+
pump.
EXPERIMENTAL APPROACH
Action potentials (APs) were recorded from canine papillary muscles and Purkinje fibres by microelectrodes. NCX current (INCX)
was determined in ventricular cardiomyocytes utilizing the whole-cell patch clamp technique. Ca2+i transients (CaTs) were
monitored with a Ca2+-sensitive fluorescent dye, Fluo-4.
KEY RESULTS
Enhanced INaL increased the Ca2+ load and AP duration (APD). SEA0400 and ORM10103 suppressed INCX and
prevented/reversed the anemone toxin II (ATX-II)-induced [Ca2+]i rise without influencing APD, CaT or cell shortening, or
affecting the ATX-II-induced increased APD. ORM10103 significantly decreased the number of strophanthidin-induced
spontaneous diastolic Ca2+ release events; however, SEA0400 failed to restrict the veratridine-induced augmentation in
Purkinje-ventricle APD dispersion.
CONCLUSIONS AND IMPLICATIONS
Selective NCX inhibition – presumably by blocking revINCX (reverse mode NCX current) – is effective against arrhythmogenesis
caused by [Na+]i-induced [Ca2+]i elevation, without influencing the AP waveform. Therefore, selective INCX inhibition, by
significantly reducing the arrhythmogenic trigger activity caused by the perturbed Ca2+i handling, should be considered as a
promising anti-arrhythmic therapeutic strategy.
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[Ca2+]i, intracellular calcium; AP, action potential; APD, action potential duration; ATX-II, anemone toxin II; CaT,
intracellular calcium transient; EAD, early afterdepolarization; fwdNCX, forward transport mode of the sodium–calcium
exchanger; fwdINCX, forward mode NCX current; INaL, late sodium current; ORM10103, 5-nitro-2-(2-phenylchroman-6-
yloxy)pyridine; revNCX, reverse transport mode of the sodium–calcium exchanger; revINCX, reverse mode NCX current;
SEA0400, 2-(4-((2,5-difluorophenyl)methoxy)phenoxy)-5-ethoxy-aniline; TdP, Torsades de Pointes
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Introduction
The development of cardiac arrhythmias requires the con-
comitant existence of a trigger (i.e. extrasystoles, generated by
large enough membrane potential oscillations, usually
induced by marked perturbations in Ca2+i handling, leading
to Ca2+i overload) and a substrate [i.e. large enough action
potential duration (APD) dispersion between adjacent cells,
typically caused by an uneven reduction in the efficacy of
action potential (AP) repolarization] (Varro and Baczko,
2011). In physiological conditions, [Ca2+]i is tightly controlled
via a delicate balance between Ca2+ fluxes (Eisner et al., 1998);
consequently, Ca2+i overload is prevented and triggered
events are rare. Furthermore, the high conduction and fast
propagation of the electrical impulses and the homogeneous
repolarization (i.e. small APD dispersion between adjacent
cells) precede circular re-entry (Varro and Baczko, 2011).
The pivotal contribution of adverse shifts in the function
of the Na+/Ca2+ exchanger (NCX) to arrhythmogenesis was
clearly demonstrated in models of severe cardiac diseases,
such as ischaemia/reperfusion injury (Schafer et al., 2001),
heart failure (Pogwizd et al., 2001) and long-QT syndrome 3
(Nuyens et al., 2001), and were also suggested to contribute to
the onset of atrial fibrillation (Lenaerts et al., 2009) and Tor-
sades de Pointes (TdP) tachyarrhythmias (Farkas et al., 2009).
Therefore, theoretically, selective NCX inhibition should
represent a novel, promising tool against Ca2+-dependent
arrhythmias.
Nonetheless, data in the literature regarding the efficacy
and clinical perspective of NCX inhibition are controversial
(Antoons et al., 2012). NCX inhibitors have shown anti-
arrhythmic effects in heart rhythm disturbances evoked by
ischaemia/reperfusion injury in vivo (Takahashi et al., 2003),
in Langendorff-perfused hearts (Mukai et al., 2000; Elias et al.,
2001; Schafer et al., 2001; Woodcock et al., 2001; Yamamura
et al., 2001; Satoh et al., 2003; Morita et al., 2011) and in
simulated ischaemia/reperfusion models (Watano et al., 1999;
Nagy et al., 2004; Wongcharoen et al., 2006; Tanaka et al.,
2007; Namekata et al., 2009). However, while SEA0400 was
found to reduce the incidence (Nagy et al., 2004) or abolish
the development of early afterdepolarizations (EADs)
(Milberg et al., 2008), in guinea pig hearts it lacked efficacy
against aconitine-induced arrhythmias (Amran et al., 2004).
Furthermore, in Langendorff-perfused rat hearts, it even
increased the incidence and duration of arrhythmias (Feng
et al., 2006). Results from our related studies are also contra-
dictory. SEA0400 did not reduce QTc following dofetilide
application and failed to prevent the development of TdPs in
rabbits (Farkas et al., 2008; 2009), whereas in another study, it
effectively suppressed EADs, without influencing APD (Nagy
et al., 2004). In contrast, Milberg et al. found SEA0400 sub-
stantially shortened the APD and also reversed sotalol- or
veratridine-induced TdPs (Milberg et al., 2008; 2012).
Recently, Jost et al. (2013) reported that ORM10103, a novel,
more selective NCX blocker, suppressed pharmacologically-
induced delayed afterdepolarization and EADs, confirming
previous results with SEA0400 (Nagy et al., 2004).
Increased NCX activity induced by augmenting the level
of Na+ [e.g. by increasing the INaL (late sodium current) or
inhibiting the Na+/K+ pump] can lead to Ca2+i overload and
subsequently abnormal automaticity (Antoons et al., 2012).
Hence, in the present study we evaluated the efficacy of two
NCX inhibitors, SEA0400 and the more selective ORM10103,
against the arrhythmogenic consequences of the increased
[Ca2+]i load induced by augmenting [Na+]i. Furthermore, as
the efficacy of NCX inhibition may not necessarily be the
same for the trigger and substrate sides of arrhythmogenesis,
we also investigated the effect of NCX inhibition on the
[Ca2+]i overload-induced shifts in AP kinetics and APD
dispersion.
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Methods
Experiments were carried out in isolated canine cardiomyo-
cytes or cardiac multicellular preparations, harvested from 50
animals, in compliance with the Guide for the Care and Use of
Laboratory Animals (USA NIH Publication No. 86–23, revised
1985). Protocols were approved by the Ethical Committee for
Protection of Animals in Research of the University of Szeged,
Hungary (Permit No. I-74-9/2009). Experimental settings and
the protocols for anaesthesia, thoracotomy and isolation of
ventricular cardiomyocytes were as described previously
(Nagy et al., 2013).
Recording of APs in multicellular preparations
Isolated papillary muscles were obtained from the right ven-
tricle. Ventricle-Purkinje fibre preparations, excised also from
right ventricles with a free running Purkinje fibre, were used
for dual electrode recordings. Multicellular preparations were
mounted in a 40 mL glass chamber and perfused with Krebs–
Henseleit solution at 37°C. The recording pipette was filled
with 3 M KCl.
Monitoring [Ca2+]i transients in single
ventricular cardiomyocytes
Cardiomyocytes were isolated from canine left ventricles
using enzymatic protocols, as described in detail previously
(Nagy et al., 2013). [Ca2+]i transients were monitored via a Ca2+-
sensitive fluorescent dye, Fluo 4. Dye-loaded cells were moun-
ted in a low volume imaging chamber (RC47FSLP, Warner
Instruments, Hamden, CT, USA) and field-stimulated at a rate
of 1 Hz, while continuously superfused with normal Tyrode’s
solution [containing (in mM): 144 NaCl, 0.4 NaH2PO4, 4 KCl,
0.53 MgSO4, 1.8 CaCl2, 5.5 glucose and 5 HEPES; pH was
adjusted to 7.4 with NaOH]. Fluorescence measurements were
performed on the stage of an Olympus IX 71 (Olympus Cor-
poration, Tokyo, Japan) inverted fluorescence microscope. The
Ca2+-sensitive dye was excited at 480 nm and the fluorescence
emitted was detected at 535 nm. Optical signals were recorded
by a photon counting photomultiplier module (Hamamatsu,
model H7828; Hamamatsu Photonics Deutschland GmbH,
Herrsching am Ammersee, Germany) and sampled at 1 kHz.
Data acquisition and analysis were performed using a CAIRN
Optoscan System (Cairn-Research Limited, Faversham Kent,
England and Wales). Background fluorescence levels were
recorded several times during each experiment and were used
to correct raw fluorescence data.
Recording ion currents
Transmembrane currents were determined at 37°C using the
whole-cell configuration of the patch clamp technique.
Late Na current (INaL). Cardiomyocytes were perfused with a
K-free, Cs-Tyrode’s solution containing (in mM): NaCl 135,
CsCl 10, CaCl2 1, MgCl2 1, BaCl2 0.2, NaH2PO4 0.33, TEACl
10, HEPES 10, glucose 10 (pH = 7.4), supplemented with
20 μM ouabain, and 1 μM nisoldipine in order to block the
Na+/K+ pump and Ca2+ currents respectively. The pipette solu-
tion contained (in mM) CsOH 140, aspartic acid 75, TEACl
20, Mg-ATP 5, HEPES 10, NaCl 10, EGTA 20, CaCl2 10, at pH
= 7.2. [Ca2+]i was set to 160 nM using WinMaxC (Patton et al.,
2004). INaL was activated via 200 ms depolarizing pulses from
−80 mV (holding potential) to −20 mV.
NCX current (INCX). INCX was measured in Cs-Tyrode’s solu-
tion supplemented with 50 μM lidocaine to inhibit INa. The
internal solution was as above, except it contained 10 mM
NaCl. INCX was determined using voltage ramps, from −40 mV
holding potential to +60 mV then to −100 mV. Reverse and
forward INCX were calculated at +40 and −80 mV respectively.
Currents were first recorded in control solution, then in the
presence of 1 μM SEA0400 or 10 μM ORM10103, finally
10 mM NiCl2 was also added. INCX was determined as the
Ni2+-sensitive difference current.
Simultaneous determination of INaL and reverse mode INCX (revINCX).
For simultaneous determination of INaL and revINCX, the internal
solution contained 15 mM NaCl. The Ca2+-activated Cl−
current was eliminated by 100 μM niflumic acid. A 200 ms
voltage step from −80 mV (holding potential) to −20 mV was
used to determine INaL; a second step of the same duration
(+40 mV) evoked revINCX. In the control group, first the total
current was recorded, then the recording was repeated follow-
ing the application of 1 μM veratridine and finally in the
presence of 10 mM NiCl2 to completely block NCX. In the
SEA0400 group, cells were first pretreated with 1 μM SEA0400
and then recordings were performed as above. In both groups,
INCX was calculated relative to the full range defined by the
control (maximum) and Ni2+-treated (minimum) currents.
Determination of the SEA0400- or ORM10103-sensitive
current. To compare the SEA0400- and ORM10103-sensitive
currents under normal conditions and following INaL activa-
tion, INaL, ICaL and INaK were not inhibited. A typical ventricular
AP has been used as command waveform. The NCX-mediated
charge was also calculated. In the control group, the SEA0400-
and ORM10103-sensitive currents were calculated from the
composite currents recorded before and after the application
of either 1 μM SEA0400 or 10 μM ORM10103. In the anemone
toxin II (ATX-II) group, following the recording of the steady-
state current, first 2 nM ATX-II, then 1 μM SEA0400 or 10 μM
ORM10103 were applied in order to increase INaL and inhibit
INCX respectively. The SEA/ORM-sensitive NCX currents in
this group were determined as the difference current between
ATX-II alone and ATX-I I + SEA/ORM recordings.
Simultaneous determination of ICaL and forward mode INCX (fwdINCX).
Measurements were performed in Cs-Tyrode’s solution. The
internal solution contained only 5 mM NaCl in order to
restrict the contribution of the reverse mode NCX activity to
the current. The internal Ca2+ was not buffered. ICaL was acti-
vated by application of a voltage step (50 ms) from a holding
potential of −80 to 0 mV. The tail current was determined at
−80 mV. In the untreated group, the control current was com-
pared with the current stimulated by 2 μM forskolin. In the
ORM10103 group, the cells were first pretreated with 10 μM
ORM10103 and then the forskolin challenge was repeated.
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA). SEA0400 was synthesized in the Department of
Pharmaceutical Chemistry, University of Szeged. ORM10103
was provided by Orion Pharma (Espoo, Finland). Stock
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solutions were stored at 4°C. All solutions were freshly pre-
pared before the start of each experiment.
ATX-II or veratridine? In preliminary tests aimed to titrate
optimal APD lengthening in multicellular samples, ATX-II
(2 nM) and veratridine (1 μM) were effective; therefore, in this
study, we used them alternately. The only difference observed
was the somewhat slower development of the steady-state
effect of veratridine. We usually used ATX-II, except for
Purkinje-ventricle preparations, where only 0.5 μM veratri-
dine was able to induce the appropriate level of AP dispersion,
probably due to the decreased sensitivity of the endocardial
samples to ATX-II compared with papillary muscles. Veratri-
dine developed a strong effect on Purkinje strands as well.
For the intracellular calcium transient (CaT) measure-
ments, similar to multicellular samples, 2 nM ATX-II was
used. At this concentration – in contrast to veratridine –
ATX-II enhanced the magnitude of [Ca2+]i transients without
inducing abnormal decay kinetics. Such an effect of veratri-
dine is probably a consequence of its stronger APD lengthen-
ing effect. While – as shown in Figure 6 – both drugs could be
used to demonstrate the tight coupling between INaL and
revNCX (reverse transport mode of the sodium–calcium
exchanger), in the actual experimental conditions the use of
1 μM veratridine was preferred as it induced a more pro-
nounced effect on INaL decay; thus, the subsequent enhance-
ment of revINCX was also stronger. However, current/CaT and
AP measurements were recorded on different sides of ventri-
cles (left and right, respectively); NCX expression was found
to be identical between ventricles (McDonald et al., 2000).
Concentrations of the inhibitors
IC50 values reported for SEA0400 in dog ventricular cardio-
myocytes were 111 ± 43 and 108 ± 18 nM for the inward and
outward NCX currents respectively (Birinyi et al., 2005). For
ORM10103, these values were 780 nM for the inward and
960 nM for the reverse INCX (Jost et al., 2013). As our principal
aim was to test the putative efficacy of INCX inhibition against
arrhythmogenic Ca2+i elevation, we aimed to induce maximal
INCX inhibition while not interfering significantly with any
other currents present. SEA0400 was applied in 1 μM concen-
tration. At this concentration, its inhibitory effect on ICa was
20% (Birinyi et al., 2005). ORM10103 has been applied in
concentration of 10 μM in which it can exert its maximal
inhibitory effect without influencing the Ca2+ current (Jost
et al., 2013).
Statistics
Experimental data were compared and analysed using Stu-
dent’s t-test, or when needed, repeated measures ANOVA with
Bonferroni-corrected post hoc test. Differences were consid-
ered significant at P < 0.05.
Results
Activation of INaL by ATX-II
INaL was activated by 2 nM ATX-II, which is known to increase
substantially the Na+ influx due to lengthening of the inacti-
vation of INaL (Shryock et al., 2013). Application of 2 nM
ATX-II significantly increased the amplitude of INaL measured
at the end of the 200 ms depolarization (P < 0.05, n = 7/3;
Figure 1A). The second ‘n’ is the number of experimental
animals. APD90 was also increased (n = 5/5, P < 0.05;
Figure 1B), as well as the amplitude of the [Ca2+]i transient (n
= 6/3, P < 0.05; Figure 1C). Parallel to the enhancement of the
[Ca2+]i transient, cell shortening was also enhanced by ATX-II
(n = 6/3, P < 0.05; Figure 1D).
The effects of 1 μM veratridine (not shown) were rather
similar. At the end of a 200 ms depolarizing pulse to −20 mV,
the magnitude of INaL increased from −0.70 ± 0.02 to −1.62 ±
0.17 pA·pF−1 (P < 0.05, n = 7/3); the APD90 was enhanced from
207 ± 7.6 to 276 ± 5.5 ms (P < 0.05, n = 5/5). Its application
also increased the amplitude of the CaT from 0.16 ± 0.03 to
0.21 ± 0.04 AU (P < 0.05, n = 10/3).
Inhibition of NCX by SEA0400
and ORM10103
INCX was determined in cardiomyocytes superfused with
modified Tyrode’s solution as described in the Methods
section. The pipette solution contained 10 mM NaCl, and
[Ca2+]i was adjusted to ∼160 nM applying CaCl2 and EGTA as
calculated by WinMaxC software (Patton et al., 2004).
Figure 2A shows the blocking efficiency of 1 μM SEA0400 for
the reverse and forward currents (n = 7/4, P < 0.05). In spite of
this relatively high level of INCX inhibition, neither the APD90
(n = 5/5; Figure 2B), the amplitude of the [Ca2+]i transient (n =
5/3; Figure 2C), nor the half-relaxation time of the [Ca2+]i
transient (301 ± 24 ms vs. 300 ± 20 ms) was affected by the
application of 1 μM SEA0400. The magnitude of cell shorten-
ing was also unaffected (n = 5/3; Figure 2D).
Similar results were obtained with the novel NCX inhibi-
tor compound ORM10103 (10 μM), which – as expected –
caused a comparable, significant inhibition of INCX both in the
reverse as well as in the forward mode operation (n = 6/2;
Figure 3A). Again, in spite of the marked NCX blockade,
neither the APD90 (n = 5/2; Figure 3B) nor the amplitude of
the [Ca2+]i transient (n = 8/3; Figure 3C) were altered by
ORM10103, and there was no change in the magnitude of cell
shortening either (Figure 3D). However, in contrast to the
results obtained with SEA0400, a small but statistically sig-
nificant increase could be observed in the half-relaxation
time (292 ± 22 ms vs. 304 ± 23 ms, P < 0.05, n = 8/3).
Selective NCX inhibition eliminates the
ATX-II-induced increase in [Ca2+]i transient
amplitude and cell shortening
As shown previously, administration of 2 nM ATX-II signifi-
cantly increased the amplitude of the [Ca2+]i transient (n =
6/3, P < 0.05). This elevation was fully reversed by superfusion
with 1 μM SEA0400 (n = 6/3, P < 0.05; Figure 4A). The same
pattern was observed in the case of cell shortening (control:
−0.15 ± 0.01; ATX-II: −0.23 ± 0.01; and ATX-II + SEA0400:
−0.14 ± 0.01 AU, n = 6/3, P < 0.05). When SEA0400 was
applied first, it fully prevented the ATX-II-induced increase in
the amplitude of the [Ca2+]i transient (n = 5/2; Figure 4B).
Similarly, no changes were evoked by ATX-II in the magni-
tude of cell shortening after pretreatment with SEA0400
(−0.13 ± 0.03, −0.12 ± 0.02 and −0.13 ± 0.03 AU, n = 6/2).
Essentially identical results were obtained with 10 μM
ORM10103. It reversed the ATX-II-induced increase in the
[Ca2+]i transient amplitude (n = 5/2, P < 0.05; Figure 4C), or
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alternatively, it prevented its elevation by ATX-II when
ORM10103 was applied as a pretreatment (n = 5/2;
Figure 4D). The magnitude of the cell shortening followed
the shifts in [Ca2+]i both in the case of cumulative application
(control: −0.24 ± 0.07; ATX-II: −0.31 ± 0.09; and ATX-II +
ORM10103: −0.23 ± 0.07 AU, n = 5/2, P < 0.05) and in the case
of pretreatment (−0.21 ± 0.07, −0.22 ± 0.07 and −0.21 ± 0.08
AU, respectively, n = 5/2).
Suppression of the arrhythmogenic diastolic
[Ca2+]i release induced by ORM10103
In this set of experiments, the efficacy of partial INCX inhibi-
tion against arrhythmogenic diastolic [Ca2+]i release events,
evoked by a combination of strophanthidin treatment and
burst stimulation, was evaluated. Three randomly selected
groups of cells were investigated: the first group was
untreated, the second group was treated with 1 μM strophan-
thidin, whereas the third group was pretreated with 10 μM
ORM10103 before the superfusion with strophanthidin. Dias-
tolic [Ca2+]i release events were evoked by short rapid (2 Hz)
pacing and were counted during the subsequent resting
period of 2 min. Application of 1 μM strophanthidin signifi-
cantly increased the amplitude of the [Ca2+]i transients at 1 Hz
(n = 10/4, P < 0.05; Figure 5A). While ORM10103 pretreat-
ment alone had no influence on the [Ca2+]i transient, the
strophanthidin-induced [Ca2+]i load was largely reduced by
ORM10103 pretreatment (n = 10/4; Figure 5B). The relative
increase in [Ca2+]i transient amplitude was higher with stro-
phanthidin alone compared to the increase after ORM1013
pretreatment (Figure 5C). Furthermore, while in the
untreated group, spontaneous diastolic [Ca2+]i release events
were absent (Figure 5D, upper trace), a large number of
releases could be observed in response to 1 μM strophanthi-
din (Figure 5D, middle trace), which was significantly
reduced in the presence of 10 μM ORM10103 (Figure 5D,
lower trace, and Figure 5E).
Inhibition of INaL induced enhancement of
revINCX by SEA0400
In this set of experiments, simultaneous determination of INaL
and revINCX was measured, as shown in the inset of Figure 6.
Activation of revINCX was supported by buffering [Ca2+]i to
160 nM and by adding 15 mM Na+ to the pipette solution.
When applying selective INCX inhibition (SEA0400 pre-
treatment) before the veratridine superfusion, the close rela-
tionship between INaL and revINCX was largely uncoupled.
Furthermore, 1 μM SEA0400 alone did not influence the mag-
nitude of INaL, but the veratridine-induced secondary increase
in INCX due to increased Na+ load was abolished by SEA0400.
The amplitude of revINCX was 0.93 ± 0.24 pA·pF−1 in control,
which rose to 1.79 ± 0.43 pA·pF−1 in the presence of 1 μM
veratridine (Figure 6A). Pretreatment with SEA0400 reduced
Figure 1
Effect of INaL activation on APD, [Ca2+]i transient and cell shortening in canine isolated ventricular myocytes. ATX-II 2 nM significantly enhanced
the INaL current by apparently slowing its inactivation kinetics (A). As a consequence, APD was lengthened (B) and the amplitude of the [Ca2+]i
transient was also increased (C), leading to an enhanced cell shortening (D). Columns and bars represent means ± SEM values; asterisks (*) denote
significant differences from control (P < 0.05). AU represents arbitrary units.
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the secondary increase in INCX (n = 8/4, Figure 6B and C).
Some experiments, performed using 2 nM ATX-II instead of
veratridine in combination with SEA0400, gave principally
identical results (not shown).
SEA0400 and ORM10103 failed to eliminate
the APD lengthening effect of ATX-II
While selective inhibition of INCX by either SEA0400 or
ORM10103 was found to be quite effective against the ATX-
II-induced increase in cellular Ca2+ load, it completely failed
to suppress the significant lengthening of APD caused by
ATX-II. Application of 1 μM SEA0400 either before or follow-
ing the ATX-II treatment had no effect on APD (Figure 7A and
B). Similar to SEA0400, the more selective ORM10103 was
also ineffective against the ATX-II-induced APD lengthening.
Independently of the sequence of application, it failed to
prevent or even reduce significantly the APD lengthening
effect of ATX-II (Figure 7C and D).
Effect of SEA0400 on the veratridine-induced
APD dispersion in ventricle-Purkinje
preparations
The effectiveness of INCX inhibition against the INaL activation-
induced increase in AP dispersion was monitored in multi-
cellular preparations, that is, in a piece of ventricular
myocardial tissue coupled to the corresponding Purkinje
fibre. The APD90 dispersion between Purkinje and ventricle
was determined in two randomly composed experimental
groups using dual microelectrodes. In the first group, only
veratridine was applied, whereas in the second group, the
preparations were pretreated with 1 μM SEA0400 before the
exposure to veratridine. Under control conditions, AP disper-
sion was significantly increased by superfusion with 0.5 μM
veratridine (Figure 8A and C). The control APD90 dispersion
level was unaltered by pretreatment with 1 μM SEA0400;
however, the application of 0.5 μM veratridine caused an
increase in APD dispersion identical to that observed without
SEA0400 (Figure 8B and C). The increase in AP dispersion
following veratridine treatment, under control conditions,
was unaltered by 1 μM SEA0400 pretreatment (n = 6/6;
Figure 8D).
Estimation of INCX kinetics under normal
conditions and after activation of INaL by
SEA0400 and ORM10103
To further explore the relationship between INaL activation
and INCX, we attempted to characterize the kinetics of INCX
during an AP either under normal conditions or following
enhanced intracellular Na+ as a result of the activation of INaL.
In these experiments, Na+ concentration in the pipette was
set to 15 mM and Ca2+ movements were unbuffered. An
AP-like command voltage pulse was applied to mimic the
Figure 2
Effect of SEA0400 on INCX, APD and [Ca2+]i handling in canine isolated cardiac cells. INCX was determined using the conventional ramp protocol
at +40 and −80 mV, respectively, defined as a Ni2+-sensitive current. SEA0400 1 μM substantially inhibited both the reverse and the forward mode
activities of INCX (A). In contrast, neither APD90 (B) nor the [Ca2+]i transient (C) was influenced and the cell shortening (D) was also unaltered by
1 μM SEA0400.
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physiological situation. When 1 μM SEA0400 was used (as
shown in Figure 9), only a small amplitude of revINCX (carrying
a charge of 4.1 ± 2.8 fC·pF−1) could be observed in the early
phase of the AP. The reverse mode activity of INCX was
switched to a much larger forward INCX carrying −105 ±
16 fC·pF−1, the estimated net charge was −101 ± 16 fC·pF−1.
Following activation of INaL by 2 nM ATX, both the reverse
mode (outward current) and the forward mode activities
(inward current) of NCX were markedly enhanced (to 61 ± 12
and −180 ± 27 fC·pF−1, respectively, when characterized by
the transferred charge), resulting in a net charge transfer of
−119 ± 19 fC·pF−1 during the whole AP. Importantly, follow-
ing INaL activation, both the reverse and the forward compo-
nents of INCX were substantially elevated compared with the
control group, whereas the net current was only moderately
enhanced (−101 ± 16 fC·pF−1 vs. −119 ± 19 fC·pF−1, NS, n = 5/4
in both groups).
Under control conditions, the magnitudes and kinetics of
the INCX components calculated following the application of
10 μM ORM10103 were similar to those determined after the
application of SEA0400 (reverse: 11.94 ± 4.9 and forward:
−65.65 ± 20.8 fC·pF−1; net charge: −53.71 ± 16.5 fC·pF−1, n =
8/5). In sharp contrast, following the application of 2 nM
ATX, both the magnitudes and the kinetics of the ORM-
sensitive current components were markedly different from
those recorded with SEA0400 (reverse: 32.63 ± 8.1 forward:
−164.2 ± 32.7 fC·pF−1; net charge: −147.86 ± 42.84 fC·pF−1, n =
8/5). Indeed, the difference between net charges was found to
be statistically significant (−53.71 ± 16.5 fC·pF−1 vs. −147.86 ±
42.84 fC·pF−1).
It should be noted that in the case of SEA0400, this
experimental arrangement may have serious limitations in
estimating INCX components quantitatively as it cannot effec-
tively inhibit INCX without inhibiting ICa (at 1 μM about 20%)
(Birinyi et al., 2005). In contrast, ORM10103 had no marked
effect on ICa (Jost et al., 2013). Furthermore, the AP lengthen-
ing effect of INaL activation was not taken into account in
calculations, consequently the amount of extra Ca2+ entry via
ICaL during the longer plateau phase was ignored.
ORM10103 10 μM failed to prevent
forskolin-induced tail current enhancement
In this set of experiments, the Ca2+-activated fwdNCX
(forward transport mode of the NCX) current was deter-
mined, as shown in the inset of Figure 10. The activation of
fwdNCX was enhanced by unbuffered intracellular Ca2+, low
Na+ in the pipette solution (5 mM), hyperpolarized mem-
brane potential (−80 mV) and forskolin (2 μM)-stimulated
Ca2+ influx.
As shown in Figure 10A and C, in the untreated group,
the magnitude of the tail current was significantly increased
following the application of forskolin (P < 0.05, n = 7/3). In
Figure 3
Effect of NCX inhibition by ORM10103 on INCX, APD and [Ca2+]i. Using the conventional ramp protocol, 10 μM ORM10103 efficiently inhibited
INCX in both transport modes of the exchanger (A). Like SEA0400, ORM10103 also failed to modulate APD90 (B), the amplitude of the [Ca2+]i
transient (C) or cell shortening (D).
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the other group, 10 μM ORM1003 was applied before the
exposure to 2 μM forskolin to test the efficacy of ORM in
preventing the secondary increase in fwdINCX current
(Figure 10B and C). The ORM10103 per se did not change the
magnitude of NCX tail current (−0.71 ± 0.1 pA·pF−1 vs. −0.63
± 0.1 pA·pF−1, NS, n = 7; not shown in Figure 10B). Following
the application of ORM10103, the forskolin challenge was
repeated. While the increase in the tail current was still sig-
nificant (−0.63 ± 0.1 pA·pF−1 vs. 1.34 ± 0.58 pA·pF−1, P < 0.05,
n = 7/3), the quantitative comparison of the two groups
clearly showed that in the presence of ORM10103, the
increase was significantly lower than in the untreated group
(−2.75 ± 0.3 pA·pF−1 vs. 1.34 ± 0.58 pA·pF−1, P < 0.05, n = 7/3).
Furthermore, the activation of the ICa (measured at the end of
the 50 ms pulse) also had a tendency to decrease (−5.35 ±
0.6 pA·pF−1 vs. −3.72 ± 0.5 pA·pF−1, NS, n = 7/3).
Figure 4
Demonstration of the efficacy of NCX inhibition against the INaL activation-induced [Ca2+]i load. If applied first, 2 nM ATX-II significantly enhanced
the magnitude of the [Ca2+]i transient, but this increase was diminished by subsequent application of 1 μM SEA0400 (A). In contrast, when 1 μM
SEA0400 was applied as a pretreatment, the secondary administration of ATX-II failed to enhance the [Ca2+]i transient (B). The same pattern of
results was obtained with 10 μM ORM10103 (C and D respectively). The ATX-II-induced enhancement of the Ca2+i transient was reversed by
ORM10103 (C). Statistical significances were verified by repeated measures ANOVA plus Bonferroni post hoc test. Columns and bars are means ±
SEM. *Denote significant differences from control, while #denote significant differences from the ATX-II-treated group (P < 0.05).
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Discussion
In the present study, the potential anti-arrhythmic effect of
selective INCX inhibition in conditions of [Na+]i elevation-
induced Ca2+i load was evaluated using the most selective
NCX inhibitors available. SEA0400 is well characterized: it
has good or at least reasonable selectivity, although it exhibits
a moderate inhibitory effect on ICa (Birinyi et al., 2005). A
concentration of 1 μM SEA0400 was the first ‘selective’ INCX
inhibitor widely used in corresponding studies. Recently, the
Figure 5
Anti-arrhythmic efficacy of ORM10103 during a strophanthidin challenge. Inhibition of the transport activity of the Na+/K+ pump with 1 μM
strophanthidin resulted in significantly enhanced [Ca2+]i transient (A). Pretreatment with 10 μM ORM10103 markedly reduced the effect of the
subsequently applied strophanthidin (B, C). In the absence of strophanthidin (control), spontaneous diastolic Ca2+ release was not observed
following a short period of rapid (2 Hz) pacing (D, upper trace). In contrast, rapid pacing induced multiple arrhythmogenic Ca2+ release events,
presumably resulting in delayed afterdepolarization in the presence of 1 μM strophanthidin (D, middle trace). Following 10 μM ORM10103
pretreatment, the same strophanthidin challenge was much less effective at evoking spontaneous Ca2+ release (D, lower trace, and E). In (B), the
statistical significance level was verified by repeated measures ANOVA plus Bonferroni post hoc test; *denote significant differences from control,
while #denote significant differences from the ORM10103-treated group (P < 0.05). In the case of (C) and (E), *indicate significant differences from
the strophanthidin-treated group.
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novel, more selective INCX inhibitor, ORM10103, was reported
to have EC50 values of 0.78/0.96 μM for forward/reverse INCX
respectively (Jost et al., 2013). ORM10103 even at a high
concentration (10 μM) has no detectable effect on further
transmembrane currents, except for minimal suppression of
IKr (Jost et al., 2013). In this study, SEA0400 and ORM10103
were applied alternately. Since both the increase in [Na+]i-
generated Ca2+ load via revNCX transport and the increase in
fwdNCX activity may significantly contribute to APD prolon-
gation, NCX inhibition is expected to be anti-arrhythmic in
this model.
In the first part of the study, the basic pharmacological
effects of the applied agents (ATX-II, SEA0400 and
ORM10103) were tested on the corresponding membrane
current and a few important physiological parameters, such
as APD, CaT amplitude and cell shortening (Figures 1–3). In
the second set of experiments, the effects of selective
INCX inhibition on [Ca2+]i homeostasis were evaluated under
‘close to physiological’ conditions (Figure 4), in a highly
arrhythmogenic state (Figure 5). The results summarized in
Figure 6 may provide a feasible explanation for the data pre-
sented in Figures 4 and 5. In the third part of this study, the
effects of selective INCX inhibition on AP parameters were
investigated under conditions corresponding to studies on
[Ca2+]i homeostasis (Figures 7–9). In the final part of the
study, we investigated the effect of ‘selective’ fwdINCX inhibi-
tion in order to explore its anti-arrhythmic mechanism and
inability to modulate physiological CaT. To characterize these
effects, two principal experimental arrangements were
applied. (i) If the INa activator was applied before the INCX
blockade, the question was whether selective NCX inhibition
is able to reverse the INaL or Na+/K+ pump-induced APD prolon-
gation or [Ca2+]i rise. (ii) When the NCX inhibitor was applied
first, the question was whether the inhibition is able to
prevent the arrhythmogenic effects of INaL activation. Our
results indicate that while selective INCX inhibition satisfacto-
rily reversed and prevented the Na+-induced [Ca2+]i rise, it had
no apparent effect on the prolonged APD nor was the
increased ventricle-Purkinje fibre APD90 dispersion reduced.
The [Ca2+]i data directly support the potential anti-arrhythmic
efficacy of INCX inhibition, which is thought to reduce abnor-
mal automaticity due to Ca2+ overload (‘trigger side’) without
apparently influencing the ‘substrate side’ or the repolariza-
tion and dispersion of repolarization, even when this was
augmented by pharmacological means.
INCX inhibition failed to modulate basic
electrophysiological parameters in
isolated cardiomyocytes
Under control conditions – in spite of the observed marked
INCX inhibition – no apparent effect of either SEA0400 or
ORM10103 on CaT and AP parameters was observed. These
results are in line with our previous work (Birinyi et al., 2008)
and that of others using SEA0400 (Amran et al., 2004).
However, at present, it is not clear why these NCX inhibitors
failed to modulate the parameters of AP, CaT and contractil-
ity. Compared with previous studies (Weber et al., 2002;
2003), our data seem to support the notion that under
normal conditions, only a small net INCX is evoked during the
AP. Consequently, the AP modulator effect of this small
Figure 6
Effect of 1 μM SEA0400 on the veratridine-induced modulation of revINCX. Activation of INaL (determined at −20 mV) by 1 μM veratridine resulted
in an enhanced revINCX (determined at +40 mV) (A), which was prevented by pretreatment with 1 μM SEA0400 (B, C). NCX currents were defined
as the Ni2+-sensitive currents. The pulse protocol applied is displayed in the inset.
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current may be fully compensated for by other repolarizing
transmembrane currents, that is, by a strong repolarization
reserve of the cardiomyocytes (Biliczki et al., 2002). In the
normal situation, the reduction in Ca2+ efflux via fwdINCX inhi-
bition failed to induce a net [Ca2+]i rise. The reason may be
either a concomitant reduction in revINCX (thus preventing the
Ca2+i gain during depolarization) or the unblocked fraction of
fwdINCX is large enough to generate the Ca2+ efflux required for
normal relaxation, or both. The lack of effect of both inhibi-
tors may contradict the hypothesis (Hobai and O’Rourke,
2004) that INCX inhibition could, indeed, be a highly effective
pharmacological tool to enhance cardiac contractility, which
can be exploited for the treatment of heart failure.
NCX inhibition reverses or prevents the
INaL-induced [Ca2+]i rise
Both NCX inhibitors effectively reduced previously increased
[Ca2+]i and enhanced cell shortening or, alternatively, pre-
vented the INaL-mediated rise in [Ca2+]i. If ATX-II was added
first, the increased Na+ influx might promote revNCX activity,
leading to a rise in [Ca2+]i and augmented CaTs. Subsequent
Figure 7
NCX inhibition has no effect on the INaL activation-induced APD lengthening. The experimental protocol was identical to that used in Figure 4.
In contrast to [Ca2+]i transient measurements, NCX inhibition was ineffective against the INaL activation-induced APD90 prolongation. Neither
SEA0400 (A, B) nor ORM10103 (C, D) reversed or even substantially decreased the lengthening of APD, leading frequently to generation of EADs.
Statistical significances were verified using repeated measure ANOVA plus Bonferroni post hoc test. Columns and bars represent means ± SEM.
*Denote significant differences from control, while #from the group pretreated with either SEA0400 or ORM10103 (P < 0.05).
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application of an INCX inhibitor reduced the enhanced revINCX
and limited any further Ca2+ influx and subsequent elevation
of [Ca2+]i. The apparent failure of INaL activation to increase
[Ca2+]i following NCX blockade clearly indicates the domi-
nance of the reverse mode inhibition in this condition.
Partial NCX inhibition by ORM10103
reduces the incidence of diastolic Ca2+ release
Data shown in Figure 4 support a direct anti-arrhythmic
effect of selective INCX inhibition via modulation of [Ca2+]i.
Figure 8
NCX inhibition is ineffective against increased AP dispersion induced by activation of INaL. In these experiments, ventricular and Purkinje APs were
simultaneously determined using two sharp microelectrodes. Ventricle-Purkinje dispersion was defined as the difference between the correspond-
ing APD90 values. Dispersion measured in the control group (A, lower box) was largely increased by 0.5 μM veratridine (A, upper box). Neither
APD was significantly affected by pretreatment with 1 μM SEA0400 (B). In addition, dispersion in the presence of SEA0400 and its veratridine-
induced increase (B, lower and upper boxes, respectively) were practically the same as those determined in the control group. Average values of
dispersion obtained in the control and SEA0400 pretreated groups before and after veratridine are summarized in (C) and (D) respectively.
*Denote significant differences from control, while #) denote significant differences from the group pretreated with SEA0400 (P < 0.05).
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This hypothesis has been tested by pharmacological inhibi-
tion of the Na+/K+ pump by strophanthidin, known to cause
AP shortening (Pueyo et al., 2010), increased [Na+]i and sub-
sequent SR Ca2+ overload, leading to arrhythmogenic Ca2+
release events (Satoh et al., 2000). ORM10103 substantially
reduced the strophanthidin-induced rise in [Ca2+]i and signifi-
cantly decreased the number of pacing-induced diastolic
releases. This effect may be a consequence of a major reduc-
tion in the revNCX-mediated SR Ca2+ overload. The beneficial
effect of NCX inhibition under these conditions – consider-
ing also the previous results – could be best explained by the
observation that perturbation of Ca2+i handling in this case
was mediated only by revNCX.
Direct coupling between INaL and Ca2+
handling via revINCX
To better understand the results shown in Figures 4 and 5,
additional experiments were performed. The efficacy of INCX
inhibition against the INaL-mediated increase in [Ca2+]i can be
satisfactorily explained by supposing the existence of a
‘revNCX-mediated direct coupling’ between Na+ influx and
[Ca2+]i rise, as also suggested by previous studies (Despa et al.,
2002; Verdonck et al., 2004). To better characterize this hypo-
thetical crosstalk, a tight interaction was modelled using a
two-step protocol, as shown in Figure 6. The veratridine-
induced INa increase led to a net gain in [Na+]i, subsequently
Figure 9
Estimation of INCX as a SEA0400- or ORM10103-sensitive current during an AP. In order to estimate the kinetics of NCX during a representative
AP, (A) SEA0400 and ORM10103 were applied, and the NCX current was estimated as a subtracted current. Under control conditions, only
negligible (outward) revINCX could be observed during the early phase of the AP. The current rapidly turned into (inward) fwdINCX (see B and C, open
squares). Application of 2 nM ATX-II (B and C, filled square) induced an apparent increase in the composite current; thus, after current subtraction,
the amplitude of the reverse component was enhanced, the reversal time delayed (see also the bar graphs in D, left for SEA0400 right for
ORM10103). The amplitude of the forward component was also enhanced (bar graphs in E, left for SEA0400 right for ORM10103). Note that the
net charge carried by a current component may change differently from the amplitude of the respective peak current.
BJPNCX inhibition and triggered arrhythmias
British Journal of Pharmacology (2014) 171 5665–5681 5677
shifting the reversal potential of NCX towards the more nega-
tive values. At the test potential of +40 mV, this shift favours
Ca2+ influx via the enhanced revINCX, simultaneously generat-
ing a large outward current. In an additional set of experi-
ments, this secondary increase in revINCX was fully abolished by
pretreatment with 1 μM SEA0400. In summary, these data
support a pivotal role of the INaL activation-coupled revINCX
increase in cardiac arrhythmogenesis and may explain the
beneficial anti-arrhythmic effects of NCX inhibition (see
Figures 4 and 5).
Failure of selective NCX inhibition to
modulate ventricular APD and reduce
ventricle-Purkinje repolarization dispersion
In contrast to the CaT data, selective NCX inhibition failed to
modulate APD – either as pretreatment or following the expo-
sure to ATX-II (Figure 7). NCX inhibition also failed to protect
or even reduce the INaL-induced large increase in ventricle-
Purkinje APD dispersion (Figure 8). The NCX inhibition-
induced uncoupling between INaL and Ca2+i handling may also
be effective under these conditions; however, it seems to exert
only a minor effect on APD. Furthermore, considering the
similar ineffectiveness of these inhibitors on APD, we con-
cluded that ORM10103 should have negligible effect on
increased APD dispersion. This observation contradicts the
results of Milberg et al. (2008) but supports the findings of
Farkas et al. (2008; 2009). The reason for the discrepancy
between our present findings and those of Milberg et al. is
unclear. It could be due to different experimental conditions,
methods of investigation and/or species differences. Hence,
the elusive nature of the inhibitory effect of SEA0400 on ICa
and NCX needs to be elucidated in further experiments.
The reason for the lack of effect on APD seems to be rather
complex. Theoretically, the lengthening of APD following the
enhancement of INaL may have two sources: (i) a direct source,
that is, the effect of the increased INaL on APD, and (ii) an
indirect source, that is, the role of INCX in defining the actual
APD. The reasonable assumption that inhibition of NCX has
no direct effect on INaL may partially explain its failure to
counteract the prolongation of the APD. Also, direct estima-
tion of INCX kinetics during an AP is complicated following the
application of ATX-II. In this study, we approximated INCX as
the SEA0400- or ORM10103-sensitive current (see Figure 9).
In both cases, following the activation of INaL, both revINCX and
fwdINCX were likely to be enhanced. The concomitant inhibi-
tion of both currents and the relatively small INCX found in
the range of APD90 suggest the limited contribution of this
current to ventricular repolarization under normal condi-
tions. Interestingly, the kinetics of the ORM10103-sensitive
and SEA0400-sensitive currents were moderately different fol-
lowing the application of ATX. As this protocol has major
limitations, care should be taken when reaching a conclu-
sion. We assume that the observed discrepancy is primarily a
Figure 10
Estimation of fwdINCX inhibition by 10 μM ORM10103 during Ca2+i load. In the ORM10103-untreated group (A), compared with control, 2 μM
forskolin markedly enhanced the ICa and the NCX tail current (C, upper panel). Pretreatment with 10 μM ORM10103 had no apparent effect on
the baseline current (the baseline curve is not shown), but 2 μM forskolin still significantly increased both currents (B, C).
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consequence of the higher selectivity of ORM10103 and that
the ORM10103-sensitive current may better approximate the
real kinetics of the NCX current.
Taken together with our CaT and AP data, an alternative
explanation may also be feasible. Following INaL activation,
parallel to the APD prolongation, [Ca2+]i also seemed to
increase. However, subsequent inhibition of NCX reduced
[Ca2+]i without an apparent effect on APD. It is possible that a
primary reduction in CaT via negative feedback prolongs ICa
inactivation and subsequently lengthens APD. Therefore, if
NCX inhibition had any direct effect on APD (i.e. INCX-
mediated reduction), it would be largely reduced by this indi-
rect mechanism (i.e. ICaL-mediated prolongation). NCX
inhibition, following the INaL-induced rise in [Ca2+]i, may have
two parallel, but opposite effects on APD: directly, it may
shorten APD via inhibition of INCX, and indirectly – due to its
reducing effect on [Ca2+]i and the subsequent modulation of
ICa kinetics – it may also prolong it. Consequently, the actual
balance of these two counteracting effects may intimately
influence the overall effect of INCX inhibition on the APD; this
is hard to predict, and may significantly differ in various
arrhythmia models and species. Indeed, this complex rela-
tionship may explain the reduction in APD induced by
SEA0400, which was observed following a sotalol/veratridine
challenge (Milberg et al., 2008), and – under rather similar
experimental conditions – the increased incidence of TdP in
Langendorff-perfused rabbit hearts following dofetilide treat-
ment (Farkas et al., 2008; 2009).
The anti-arrhythmic efficacy of ORM10103
may be a consequence of revINCX inhibition
In order to clarify the anti-arrhythmic action of ORM10103,
the experiments summarized in Figure 10 were aimed at
investigating the consequences of ‘selective’ fwdINCX inhibi-
tion. We found that under normal conditions (i.e. without
stimulation of the Ca2+ influx with forskolin), 10 μM
ORM10103 did not inhibit the tail current determined at −80
mV, which may be considered as fwdINCX. This result seems to
contradict the data shown in Figure 3A, determined using the
‘traditional’ ramp protocol and may indicate that NCX inhi-
bition during intact Ca2+ cycling provides more realistic infor-
mation about its inhibitory efficacy. This result may also help
to properly interpret the apparent failure of NCX inhibitors
to modulate normal Ca2+ transient kinetics (Figure 3B). None-
theless, we also found a statistically significant effect of
ORM10103 on fwdINCX during Ca2+i load (Figure 10A–C) since
the compound reduced the forskolin-induced increase in
NCX tail current. This finding further emphasizes the impor-
tance of revINCX inhibition in the anti-arrhythmic efficacy of
ORM10103, but it also justifies the need for additional experi-
mental work.
Computer simulations of NCX current during
an AP
A number of modelling studies aimed to simulate the kinetics
of INCX during an AP. In spite of the experimental and simu-
lation efforts, there is no consistent agreement about the
reversal point of the NCX current during a ventricular AP. The
guinea pig model of Luo and Rudy (1994) predicted a rela-
tively long period for reverse mode activity (∼100 ms). Similar
results were published for the guinea pig model of Faber and
Rudy (2000). In contrast, the rabbit model developed by
Weber et al. (2002) predicted a much shorter period of reverse
activity (∼10 ms). Similarly, in a human ventricular AP model
developed by Grandi et al. (2009), an inward NCX current
was present during most of the plateau phase. In contrast, in
the canine AP models described by Armoundas et al. (2003)
and Greenstein et al. (2006), the reversal point was calculated
to follow the plateau phase and the NCX was suggested to
carry primarily outward current during the AP. Although
interspecies differences (AP shape, Ca2+i and Na+i levels) may
play an important role in the diversity of data, it should also
be emphasized that even results derived from models
designed for the same species (e.g. in guinea pig models) may
differ significantly (Noble et al., 1991; 1998; Faber and Rudy,
2000). The large diversity of the simulated results may pri-
marily be a consequence of the inconsistent interpretation of
submembrane Ca2+ and Na+ movements and membrane
potential dynamics, which are the main modulators of NCX
activity.
Regarding the function of NCX inhibition on APD, Li and
Rudy (2011) concluded that at a high pacing rate, in Purkinje
and ventricular cells, INaK-mediated [Na+]i accumulation is the
most important factor causing APD shortening. However, in
Purkinje cells, INCX and INaL are also important contributors (Li
and Rudy, 2011). In the computer model of NCX knockout
mice by Sarai et al. (2006), the inward current decreased and
the APD slightly shortened following 70% inhibition of INCX.
In the study published by Amran et al. (2004), an integrated
mathematical model was applied to investigate whether the
NCX plays a role in aconitine-induced arrhythmias. The
model well mimicked the aconitine-induced membrane oscil-
lations; however, the fit was made worse by SEA0400 and the
study concluded that the oscillations could not be suppressed
by NCX inhibition.
Our present experimental results seem to support the
simulated results from the Weber model (Weber et al., 2002),
which predicted a predominantly inward INCX with a rela-
tively short period of reverse mode activity during AP and the
assumption that the NCX reversal point is within the first
10 ms of the AP.
Conclusions and perspectives
Our present data support the hypothesis that selective, partial
NCX inhibition may, by restricting the Na+-induced [Ca2+]i
elevation, have an anti-arrhythmic effect; this protective
effect is mediated primarily by its inhibitory effect on revINCX.
Therefore, NCX inhibition can be considered as a promising
therapeutic strategy against Ca2+ overload-induced, revNCX-
mediated cardiac arrhythmias.
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